Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 4;4(1):vdac124. doi: 10.1093/noajnl/vdac124

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Quantitative comparison of changes in nrCBV, FLAIR volume, and ADC after IDH inhibitor treatment. After 3–6 weeks of IDH inhibitor treatment, there was (A, B) a significant increase in nrCBV (P = .004) (C) and no change in FLAIR volume (P = .23) (D) or ADC (P = .52). After 2–4 months of IDH inhibitor treatment, (E, F) nrCBV, (G) FLAIR volume, and (H) ADC appeared to stabilize. Asterisks (*) indicate P < .05. IDH, isocitrate dehydrogenase; nrCBV, normalized relative cerebral blood volume; ADC, apparent diffusion coefficient.